AG
OMGA

Artal Group’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Artal Group’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,323,530
Closed -$2.74M – 109
2024
Q2 		$2.74M Hold
1,323,530
– – 0.07% 70
2024
Q1 		$4.83M Hold
1,323,530
– – 0.12% 66
2023
Q4 		$3.98M Sell
1,323,530
-1,209,515
-48% -$2.45M 0.13% 60
2023
Q3 		$5.45M Hold
2,533,045
– – 0.23% 57
2023
Q2 		$14.2M Hold
2,533,045
– – 0.44% 34
2023
Q1 		$15.3M Buy
2,533,045
+259,515
+11% +$1.81M 0.91% 27
2022
Q4 		$13M Hold
2,273,530
– – 0.72% 35
2022
Q3 		$12.3M Hold
2,273,530
– – 0.53% 40
2022
Q2 		$8.64M Hold
2,273,530
– – 0.46% 42
2022
Q1 		$14.2M Hold
2,273,530
– – 0.59% 38
2021
Q4 		$25.8M Hold
2,273,530
– – 0.7% 36
2021
Q3 		$42.9M Buy
+2,273,530
New +$43.6M 0.96% 26

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artal Group's OMGA Position: Q3 2024 in Review

Artal Group sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q3 2024, closing a stake of 1,323,530 shares — an estimated $2.74M sold.

Artal Group first reported a position in OMGA in Q3 2021 and held it in 12 quarters. The position peaked at $42.9M in Q3 2021. 54 funds tracked by Wall St. Rank hold OMGA as of Q3 2024.

  • Artal Group reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 1,323,530 Omega Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $2.74M.
  • Artal Group first reported a position in Omega Therapeutics, Inc. Common Stock in Q3 2021 and held it in 12 quarters.
  • Artal Group's Omega Therapeutics, Inc. Common Stock position peaked at $42.9M in Q3 2021.
  • 54 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.